JOURNAVX®

Hold Company

VERTEX PHARMS INC

Learn More

Dosage and Administration

TABLET;ORAL

Specification

50MG

Indication

Journavx® is indicated for the treatment of moderate to severe acute pain in adults.

Use

Instructions for Use

API

SUZETRIGINE

API Structure

We Supply

SUZETRIGINE

Drug Patent

Patent No	Expiration Date
11834441	2040/12/4

API Patent

Patent No	Expiration Date
11834441	2040/12/4

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.